Ensysce Biosciences, Inc (ENSC): Price and Financial Metrics
ENSC Price/Volume Stats
| Current price | $0.85 | 52-week high | $38.52 |
| Prev. close | $0.81 | 52-week low | $0.77 |
| Day low | $0.79 | Volume | 22,402 |
| Day high | $0.85 | Avg. volume | 324,071 |
| 50-day MA | $1.13 | Dividend yield | N/A |
| 200-day MA | $2.84 | Market Cap | 2.66M |
ENSC Stock Price Chart Interactive Chart >
Ensysce Biosciences, Inc (ENSC) Company Bio
Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.
Latest ENSC News From Around the Web
Below are the latest news stories about ENSYSCE BIOSCIENCES INC that investors may wish to consider to help them evaluate ENSC as an investment opportunity.
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical Study~ Enrollment Completion Signifies Critical Progress to Phase 3 of PF614 ~~ Trial Results Expected in December 2023 ~SAN DIEGO, CA / ACCESSWIRE / November 16, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage ... |
ENSC Releases Earnings and Highlights ProgressBy Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Earnings Update • Cash and cash equivalents were $1.5 million at the end of 3Q, down from $3.8 million at the end of 1Q. o During 3Q, Ensysce (NASDAQ:ENSC) completed a convertible note financing offer that netted the company roughly $560,000 before fees and offering expenses, with the potential for another $1.13 million upon |
Ensysce Biosciences Reports Third Quarter 2023 Financial ResultsPF614-201 Clinical Study Results Expected by End of YearSAN DIEGO, CA / ACCESSWIRE / November 9, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription ... |
Ensysce Biosciences Secures $1.7 Million Convertible Note FinancingAdditional Funding from Investor Cohort Validates Company's MissionSAN DIEGO, CA / ACCESSWIRE / October 24, 2023 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage company applying transformative ... |
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360Poster Presentation to Showcase the Optimization Process of Ensysce's PF614-MPAR FormulationSAN DIEGO, CA / ACCESSWIRE / October 18, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage company applying transformative ... |
ENSC Price Returns
| 1-mo | -7.72% |
| 3-mo | -52.78% |
| 6-mo | -63.98% |
| 1-year | -97.56% |
| 3-year | -99.97% |
| 5-year | -100.00% |
| YTD | -90.56% |
| 2022 | -99.20% |
| 2021 | -62.20% |
| 2020 | -94.03% |
| 2019 | 6.11% |
| 2018 | N/A |
Loading social stream, please wait...